|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD, Sauer AG, Fedewa SA,
Butterly LF, Anderson JC, Cercek A, Smith RA and Jemal A:
Colorectal cancer statistics, 2020. CA Cancer J Clin. 70:145–164.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Murphy CC, Harlan LC, Lund JL, Lynch CF
and Geiger AM: Patterns of colorectal cancer care in the United
States: 1990-2010. J Natl Cancer Inst. 107:djv1982015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Keum N and Giovannucci E: Global burden of
colorectal cancer: emerging trends, risk factors and prevention
strategies. Nat Rev Gastroenterol Hepatol. 16:713–732. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sanchez-Gundin J, Fernandez-Carballido A
M, Martinez-Valdivieso L, Barreda-Hernandez D and Torres-Suarez AI:
New trends in the therapeutic approach to metastatic colorectal
cancer. Int J Med Sci. 15:659–665. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Oh DY and Bang YJ: HER2-targeted
therapies-a role beyond breast cancer. Nat Rev Clin Oncol.
17:33–48. 2020. View Article : Google Scholar
|
|
7
|
Ferguson FM and Gray NS: Kinase
inhibitors: The road ahead. Nat Rev Drug Discov. 17:353–377. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Meric-Bernstam F and Mills GB: Overcoming
implementation challenges of personalized cancer therapy. Nat Rev
Clin Oncol. 9:542–548. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sala E, Mologni L, Truffa S, Gaetano C,
Bollag GE and Gambacorti-Passerini C: BRAF silencing by short
hairpin RNA or chemical blockade by PLX4032 leads to different
responses in melanoma and thyroid carcinoma cells. Mol Cancer Res.
6:751–759. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chung CH, Mirakhur B, Chan E, Le QT,
Berlin J, Morse M, Murphy BA, Satinover SM, Hosen J, Mauro D, et
al: Cetuximab-induced anaphylaxis and IgE specific for
galactose-alpha-1,3-galactose. N Engl J Med. 358:1109–1117. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cohen MH, Gootenberg J, Keegan P and
Pazdur R: FDA drug approval summary: Bevacizumab plus FOLFOX4 as
second-line treatment of colorectal cancer. Oncologist. 12:356–361.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Le XF, Pruefer F and Bast RC Jr:
HER2-targeting antibodies modulate the cyclin-dependent kinase
inhibitor p27Kip1 via multiple signaling pathways. Cell Cycle.
4:87–95. 2005. View Article : Google Scholar
|
|
13
|
Curigliano G and Criscitiello C: Successes
and limitations of targeted cancer therapy in breast cancer. Prog
Tumor Res. 41:15–35. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Holcmann M and Sibilia M: Mechanisms
underlying skin disorders induced by EGFR inhibitors. Mol Cell
Oncol. 2:e10049692015. View Article : Google Scholar
|
|
15
|
Welsh SJ and Corrie PG: Management of BRAF
and MEK inhibitor toxicities in patients with metastatic melanoma.
Ther Adv Med Oncol. 7:122–136. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Spaans JN and Goss GD: Drug resistance to
molecular targeted therapy and its consequences for treatment
decisions in non-small-cell lung cancer. Front Oncol. 4:1902014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yanagisawa M, Kurihara H, Kimura S, Tomobe
Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K and Masaki T: A novel
potent vasoconstrictor peptide produced by vascular endothelial
cells. Nature. 332:411–415. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Inoue A, Yanagisawa M, Kimura S, Kasuya Y,
Miyauchi T, Goto K and Masaki T: The human endothelin family: Three
structurally and pharmacologically distinct isopeptides predicted
by three separate genes. Proc Natl Acad Sci USA. 86:2863–2867.
1989. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Davenport AP, Hyndman KA, Dhaun N, Southan
C, Kohan DE, Pollock JS, Pollock DM, Webb DJ and Maguire JJ:
Endothelin. Pharmacol Rev. 68:357–418. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sakurai T, Yanagisawa M, Takuwa Y,
Miyazaki H, Kimura S, Goto K and Masaki T: Cloning of a cDNA
encoding a non-isopeptide-selective subtype of the endothelin
receptor. Nature. 348:732–735. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rosanò L, Spinella F and Bagnato A:
Endothelin 1 in cancer: Biological implications and therapeutic
opportunities. Nat Rev Cancer. 13:637–651. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bagnato A and Natali PG: Endothelin
receptors as novel targets in tumor therapy. J Transl Med.
2:162004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rosanò L and Bagnato A: Endothelin
therapeutics in cancer: Where are we? Am J Physiol Regul Integr
Comp Physiol. 310:R469–R475. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bondurand N, Dufour S and Pingault V: News
from the endothelin-3/EDNRB signaling pathway: Role during enteric
nervous system development and involvement in neural
crest-associated disorders. Dev Biol. 444(Suppl 1): S156–S169.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kohan DE, Rossi NF, Inscho EW and Pollock
DM: Regulation of blood pressure and salt homeostasis by
endothelin. Physiol Rev. 91:1–77. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nelson JB, Udan MS, Guruli G and Pflug BR:
Endothelin-1 inhibits apoptosis in prostate cancer. Neoplasia.
7:631–637. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Smith MP, Rowling EJ, Miskolczi Z,
Ferguson J, Spoerri L, Haass NK, Sloss O, McEntegart S, Arozarena
I, von Kriegsheim A, et al: Targeting endothelin receptor
signalling overcomes heterogeneity driven therapy failure. EMBO Mol
Med. 9:1011–1029. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Laurberg JR, Jensen JB, Schepeler T, Borre
M, Orntoft TF and Dyrskjot L: High expression of GEM and EDNRA is
associated with metastasis and poor outcome in patients with
advanced bladder cancer. BMC Cancer. 14:6382014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Minchenko DO, Tsymbal DO, Riabovol OO,
Viletska YM, Lahanovska YO, Sliusar MY, Bezrodnyi BH and Minchenko
OH: Hypoxic regulation of EDN1, EDNRA, EDNRB, and ECE1 gene
expressions in ERN1 knockdown U87 glioma cells. Endocr Regul.
53:250–262. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kawai K, Viars C, Arden K, Tarin D,
Urquidi V and Goodison S: Comprehensive karyotyping of the HT-29
colon adenocarcinoma cell line. Genes Chromosomes Cancer. 34:1–8.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
32
|
Schust J, Sperl B, Hollis A, Mayer TU and
Berg T: Stattic: A small-molecule inhibitor of STAT3 activation and
dimerization. Chem Biol. 13:1235–1242. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gatfield J, Mueller Grandjean C, Sasse T,
Clozel M and Nayler O: Slow receptor dissociation kinetics
differentiate macitentan from other endothelin receptor antagonists
in pulmonary arterial smooth muscle cells. PLoS One. 7:e476622012.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sidharta PN, van Giersbergen PL, Halabi A
and Dingemanse J: Macitentan: Entry-into-humans study with a new
endothelin receptor antagonist. Eur J Clin Pharmacol. 67:977–984.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hong IS, Coe HV and Catanzaro LM:
Macitentan for the treatment of pulmonary arterial hypertension.
Ann Pharmacother. 48:538–547. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang J, Gareri C and Rockman HA:
G-protein-coupled receptors in heart disease. Circ Res.
123:716–735. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hauser AS, Attwood MM, Rask-Andersen M,
Schiöth HB and Gloriam DE: Trends in GPCR drug discovery: New
agents, targets and indications. Nat Rev Drug Discov. 16:829–842.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Rosanò L, Cianfrocca R, Tocci P, Spinella
F, Castro VD, Caprara V, Semprucci E, Ferrandina G, Natali PG and
Bagnato A: Endothelin A receptor/β-arrestin signaling to the Wnt
pathway renders ovarian cancer cells resistant to chemotherapy.
Cancer Res. 74:7453–7464. 2014. View Article : Google Scholar
|
|
39
|
Kelland NF, Bagnall AJ, Morecroft I,
Gulliver-Sloan FH, Dempsie Y, Nilsen M, Yanagisawa M, Maclean MR,
Kotelevtsev YV and Webb DJ: Endothelial ET(B) limits vascular
remodelling and development of pulmonary hypertension during
hypoxia. J Vasc Res. 47:16–22. 2010. View Article : Google Scholar
|
|
40
|
Schneider MP, Boesen EI and Pollock DM:
Contrasting actions of endothelin ET(A) and ET(B) receptors in
cardiovascular disease. Annu Rev Pharmacol Toxicol. 47:731–759.
2007. View Article : Google Scholar
|
|
41
|
Wulfing C, Eltze E, Yamini J, Wülfing P,
Bierer S, Böcker W, Hertle L, Semjonow A and Sievert KD: Expression
of the endothelin axis in bladder cancer: Relationship to
clinicopathologic parameters and long-term survival. Eur Urol.
47:593–600. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Fu W, Wu X, Yang Z and Mi H: The effect of
miR-124-3p on cell proliferation and apoptosis in bladder cancer by
targeting EDNRB. Arch Med Sci. 15:1154–1162. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Mahdi MR, Georges RB, Ali DM, Bedeer RF,
Eltahry HM, Gabr AEHZ and Berger MR: Modulation of the endothelin
system in colorectal cancer liver metastasis: Influence of
epigenetic mechanisms? Front Pharmacol. 11:1802020. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Hsu LS, Lee HC, Chau GY, Yin PH, Chi CW
and Lui WY: Aberrant methylation of EDNRB and p16 genes in
hepatocellular carcinoma (HCC) in Taiwan. Oncol Rep. 15:507–511.
2006.PubMed/NCBI
|
|
45
|
Tao K, Wu C, Wu K, Li W, Han G, Shuai X
and Wang G: Quantitative analysis of promoter methylation of the
EDNRB gene in gastric cancer. Med Oncol. 29:107–112. 2012.
View Article : Google Scholar
|
|
46
|
Yegnasubramanian S, Kowalski J, Gonzalgo
ML, Zahurak M, Piantadosi S, Walsh PC, Bova GS, Marzo AM, Isaacs WB
and Nelson WG: Hypermethylation of CpG islands in primary and
metastatic human prostate cancer. Cancer Res. 64:1975–1986. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Soh BS, Ng SY, Wu H, Buac K, Park JHC,
Lian X, Xu J, Foo KS, Felldin U, He X, et al: Endothelin-1 supports
clonal derivation and expansion of cardiovascular progenitors
derived from human embryonic stem cells. Nat Commun. 7:107742016.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Alvarez D, Briassouli P, Clancy RM,
Zavadil J, Reed JH, Abellar RG, Halushka M, Fox-Talbot K, Barrat FJ
and Buyon JP: A novel role of endothelin-1 in linking Toll-like
receptor 7-mediated inflammation to fibrosis in congenital heart
block. J Biol Chem. 286:30444–30454. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Cianfrocca R, Rosano L, Tocci P, Sestito
R, Caprara V, Castro VD, Maria RD and Bagnato A: Blocking
endothelin-1-receptor/beta-catenin circuit sensitizes to
chemotherapy in colorectal cancer. Cell Death Differ. 24:1811–1820.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wei W, Shi L, Chen W, Hu L, Chen D, Shi X,
Xiang H, Guo C and Wu Z: miR-200c regulates the proliferation,
apoptosis and invasion of gastric carcinoma cells through the
downregulation of EDNRA expression. Int J Mol Med. 41:1619–1626.
2018.
|
|
51
|
Sestito R, Cianfrocca R, Tocci P, Rosanò
L, Sacconi A, Blandino G and Bagnato A: Targeting endothelin 1
receptor-miR-200b/c-ZEB1 circuitry blunts metastatic progression in
ovarian cancer. Commun Biol. 3:6772020. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Kamran MZ, Patil P and Gude RP: Role of
STAT3 in cancer metastasis and translational advances. Biomed Res
Int. 2013:4218212013. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Corvinus FM, Orth C, Moriggl R, Tsareva
SA, Wagner S, Pfitzner EB, Baus D, Kaufmann R, Huber LA, Zatloukal
K, et al: Persistent STAT3 activation in colon cancer is associated
with enhanced cell proliferation and tumor growth. Neoplasia.
7:545–555. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Lin L, Liu A, Peng Z, Lin HJ, Li PK, Li C
and Lin J: STAT3 is necessary for proliferation and survival in
colon cancer-initiating cells. Cancer Res. 71:7226–7237. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Wendt MK, Balanis N, Carlin CR and
Schiemann WP: STAT3 and epithelial-mesenchymal transitions in
carcinomas. JAKSTAT. 3:e289752014.PubMed/NCBI
|
|
56
|
Thaete LG, Jilling T, Synowiec S, Khan S
and Neerhof MG: Expression of endothelin 1 and its receptors in the
hypoxic pregnant rat. Biol Reprod. 77:526–532. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Morikawa T, Baba Y, Yamauchi M, Kuchiba A,
Nosho K, Shima K, Tanaka N, Huttenhower C, Frank DA, Fuchs CS and
Ogino S: STAT3 expression, molecular features, inflammation
patterns, and prognosis in a database of 724 colorectal cancers.
Clin Cancer Res. 17:1452–1462. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Kankanamalage SG, Karra AS and Cobb MH:
WNK pathways in cancer signaling networks. Cell Commun Signal.
16:722018. View Article : Google Scholar
|
|
59
|
Sato A, Shimizu M, Goto T, Masuno H,
Kagechika H, Tanaka N and Shibuya H: WNK regulates Wnt signalling
and β-Catenin levels by interfering with the interaction between
β-catenin and GID. Commun Biol. 3:6662020. View Article : Google Scholar
|
|
60
|
Sulzmaier FJ, Jean C and Schlaepfer DD:
FAK in cancer: Mechanistic findings and clinical applications. Nat
Rev Cancer. 14:598–610. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Zhao J and Guan JL: Signal transduction by
focal adhesion kinase in cancer. Cancer Metastasis Rev. 28:35–49.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Yang Y, Wang Y, Che X, Hou K, Wu J, Zheng
C, Cheng Y, Liu Y, Hu X and Zhang J: Integrin alpha5 promotes
migration and invasion through the FAK/STAT3/AKT signaling pathway
in icotinib-resistant non-small cell lung cancer cells. Oncol Lett.
22:5562021. View Article : Google Scholar
|
|
63
|
Pei G, Lan Y, Chen D, Ji L and Hua ZC: FAK
regulates E-cadherin expression via p-SrcY416/p-ERK1/2/p-Stat3Y705
and PPARγ/miR-125b/Stat3 signaling pathway in B16F10 melanoma
cells. Oncotarget. 8:13898–13908. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Pulido T, Adzerikho I, Channick RN,
Delcroix M, Galiè N, Ghofrani HA, Jansa P, Jing ZC, Brun FOL, Mehta
S, et al: Macitentan and morbidity and mortality in pulmonary
arterial hypertension. N Engl J Med. 369:809–818. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Russignan A, Dal Collo G, Bagnato A,
Tamassia N, Bugatti M, Belleri M, Lorenzi L, Borsi E, Bazzoni R,
Gottardi M, et al: Targeting the endothelin-1 receptors curtails
tumor growth and angiogenesis in multiple myeloma. Front Oncol.
10:6000252020. View Article : Google Scholar
|
|
66
|
Tocci P, Cianfrocca R, Di Castro V, Rosanò
L, Sacconi A, Donzelli S, Bonfiglio S, Bucci G, Vizza E, Ferrandina
G, et al: β-arrestin1/YAP/mutant p53 complexes orchestrate the
endothelin A receptor signaling in high-grade serous ovarian
cancer. Nat Commun. 10:31962019. View Article : Google Scholar
|
|
67
|
Lee HJ, Hanibuchi M, Kim SJ, Yu H, Kim MS,
He J, Langley RR, Lehembre F, Regenass U and Fidler IJ: Treatment
of experimental human breast cancer and lung cancer brain
metastases in mice by macitentan, a dual antagonist of endothelin
receptors, combined with paclitaxel. Neuro Oncol. 18:486–496. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Kim SJ, Lee HJ, Kim MS, Choi HJ, He J, Wu
Q, Aldape K, Weinberg JS, Yung WKA, Conrad CA, et al: Macitentan, a
dual endothelin receptor antagonist, in combination with
temozolomide leads to glioblastoma regression and long-term
survival in mice. Clin Cancer Res. 21:4630–4641. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Damia G, Filiberti L, Vikhanskaya F,
Carrassa L, Taya Y, D'incalci M and Broggini M: Cisplatinum and
taxol induce different patterns of p53 phosphorylation. Neoplasia.
3:10–16. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Persons DL, Yazlovitskaya EM and Pelling
JC: Effect of extracellular signal-regulated kinase on p53
accumulation in response to cisplatin. J Biol Chem.
275:35778–35785. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Dasari S and Tchounwou PB: Cisplatin in
cancer therapy: Molecular mechanisms of action. Eur J Pharmacol.
740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Tchounwou PB, Dasari S, Noubissi FK, Ray P
and Kumar S: Advances in our understanding of the molecular
mechanisms of action of cisplatin in cancer therapy. J Exp
Pharmacol. 13:303–328. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Ohtani H, Arimoto Y, Nishio K, Kanamiya Y,
Oba H, Adachi K, Shintani M, Nakamura R and Yui S: Efficacy and
toxicity of fluorouracil, leucovorin plus oxaliplatin (FOLFOX4 and
modified FOLFOX6) followed by fluorouracil, leucovorin plus
irinotecan(FOLFIRI)for advanced or metastatic colorectal
cancer-case studies. Gan To Kagaku Ryoho. 35:1769–1774.
2008.PubMed/NCBI
|
|
74
|
Gustavsson B, Carlsson G, Machover D,
Petrelli N, Roth A, Schmoll HJ, Tveit KM and Gibson F: A review of
the evolution of systemic chemotherapy in the management of
colorectal cancer. Clin Colorectal Cancer. 14:1–10. 2015.
View Article : Google Scholar : PubMed/NCBI
|
